The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – “We are excited to advance ALN-KHK to the clinic as our first RNAi therapeutic ...

ALN-AGT is an investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen (AGT) in development for the treatment of hypertension in high unmet need populations. ALN-AGT ...

A Cornucopia of siRNA- and RNAi-based Therapeutics in Development Show Promise Researchers from academia and industry will present the latest developments in the application of interference RNA (RNAi) ...

RNA interference (RNAi) is an ancient genetic regulatory mechanism that modern-day scientists are trying to harness. Since its discovery more than 10 years ago, RNAi R&D has run the gamut from ...

DUBLIN--(BUSINESS WIRE)--The "RNA interference (RNAi) Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. Certain factors that are driving ...

Ribonucleic acid (RNA) interference is a relatively new technique in which small molecules called short interfering RNA (siRNA) can be inserted into cells to turn off a chosen gene. The potential uses ...

(MENAFN- EIN Presswire) EINPresswire/ -- The RNA interference (RNAi) technology market has been experiencing remarkable growth recently, driven by advances in genetic research and increasing interest ...

Advancing a once-annual preventive RNAi medicine designed to reduce the two key drivers of cardiovascular disease: LDL-C and blood pressure Filed application for COR-1004, a novel siRNA targeting ...